Working with TipRanks
Follow Us
Stocks
ETFs
Options
Crypto
Research Tools
Calendars
Calculators
Education
About Us
Working with TipRanks
Follow Us
Silence Therapeutics (SLN)
NASDAQ:SLN
Silence Therapeutics (SLN) Stock Price & Analysis
44 Followers
SLN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$4.55 - $17.69
Previous Close$14.58
Volume593.47K
Average Volume (3M)37.59K
Market Cap
$512.81M
Enterprise Value$423.80M
Total Cash (Recent Filing)£71.14M
Total Debt (Recent Filing)£446.00K
Price to Earnings (P/E)-10.2
Beta1.11
Next Earnings
Mar 13, 2024EPS Estimate
-$0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.43
Shares Outstanding35,893,337
10 Day Avg. Volume56,081
30 Day Avg. Volume37,590
Standard Deviation0.24
R-Squared0.08
Alpha0.00561
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)25.55
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$38.67Price Target Upside166.69% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Silence Therapeutics News
Ownership Overview
0.00%
Insiders
0.05% Mutual Funds
52.84% Other Institutional Investors
47.12% Public Companies and
Individual Investors
SLN FAQ
What was Silence Therapeutics’s price range in the past 12 months?
Silence Therapeutics lowest stock price was $4.54 and its highest was $17.69 in the past 12 months.
What is Silence Therapeutics’s market cap?
Currently, no data Available
When is Silence Therapeutics’s upcoming earnings report date?
Silence Therapeutics’s upcoming earnings report date is Mar 13, 2024 which is in 95 days.
How were Silence Therapeutics’s earnings last quarter?
Silence Therapeutics released its earnings results on Nov 14, 2023. The company reported -$0.092 earnings per share for the quarter, beating the consensus estimate of -$0.172 by $0.08.
Is Silence Therapeutics overvalued?
According to Wall Street analysts Silence Therapeutics’s price is currently Undervalued.
Does Silence Therapeutics pay dividends?
Silence Therapeutics does not currently pay dividends.
What is Silence Therapeutics’s EPS estimate?
Silence Therapeutics’s EPS estimate is -$0.08.
How many shares outstanding does Silence Therapeutics have?
Silence Therapeutics has 35,936,157 shares outstanding.
What happened to Silence Therapeutics’s price movement after its last earnings report?
Silence Therapeutics reported an EPS of -$0.092 in its last earnings report, beating expectations of -$0.172. Following the earnings report the stock price went up 2.331%.
Which hedge fund is a major shareholder of Silence Therapeutics?
Among the largest hedge funds holding Silence Therapeutics’s share is Woodline Partners LP. It holds Silence Therapeutics’s shares valued at 2M.
---
Silence Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$38.67 (166.69% Upside)
$38.67 (166.69% Upside)
Blogger Sentiment
Bullish
SLN Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 72.7K Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-6.23%
12-Months-Change
Fundamentals
Return on Equity
-166.38%
Trailing 12-Months
Asset Growth
-13.66%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Silence Therapeutics
Silence Therapeutics PLC is one of the leading companies in the ribonucleic acid (RNA) technology field. The United Kingdom-based firm researches and develops therapeutics to combat highly unmet medical needs. Its patented RNA interference platform, known as AtuRNAi is employed in vaccines to correct genetic deficiencies and infectious diseases by silencing or replacing the expression of virtually any gene in the genome, modulating expression up as well as down in a variety of organs and cell types. Its technology is currently in the clinic, in a Phase 2a pancreatic cancer trial and its income consists of license fees, milestone and option payments, grant income and fees from research and development collaborations.
---
Top 5 ETFs holding SLN
Currently, no data available
Please return soon. This page is being updated.
Up to five ETFs with an Outperform Smart Score that hold SLN. The ETFs are listed according to market value of SLN within the ETF
---